Negative findings were reported for both clinical and imaging measures in a Phase II randomized trial of riluzole in comparison to placebo in patients with very early multiple sclerosis (MS).
Jenny Powers, HCPLive
Advertisement
Articles by Jenny Powers, HCPLive
Advertisement
Latest Updated Articles
Riluzole Shows No Efficacy as a Neuroprotective Agent in Patients with Early-Stage Relapsing Remitting Multiple SclerosisPublished: October 10th 2013 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Fall 2025 Quiz: Test Your Pharmacy Knowledge!
2
FDA Approves Elinzanetant as First Nonhormonal Therapy for Menopause Vasomotor Symptoms
3
Lynkuet Access Program Aims to Help Women Save on Neurokinin-Targeted Therapy
4
Disparities in Continuous Glucose Monitor Prescriptions by Language Preference Among Adults With Type 2 Diabetes
5
